ALIPAY
12.7.2021 04:10:06 CEST | Business Wire | Press release
Portuguese football star Cristiano Ronaldo today became the winner of the Gold Trophy of the Alipay Top Scorer Awards at UEFA EURO 2020. Regarded as one of the greatest footballers of all time, Ronaldo netted five goals and made one assist at the competition. Patrik Schick from the Czech Republic was awarded the Silver Trophy, scoring five goals, while France’s Karim Benzema was the recipient of the Bronze Trophy, netting four goals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210711005035/en/
The Alipay Top Scorer trophies are the first major international football Top-Scorer trophies to embed blockchain in their design, incorporating a hash code at the base through which scoring records of the tournament’s top three scorers can be uploaded and permanently stored on a blockchain powered by AntChain. Using the hash code provided, Alipay will upload the trophy data to the blockchain, ensuring a permanent, immutable record of the top scorers’ achievements.
“Our warmest congratulations to Cristiano Ronaldo for his phenomenal performances at UEFA EURO 2020, and for winning the Alipay Top Scorer Gold Award,” said Eric Jing, Chairman and CEO of Ant Group, who presented the top scorer trophies via video from Hangzhou immediately after the final game of UEFA EURO 2020. “Just as we have used blockchain technology to permanently preserve the wonderful scoring moments of the top scorers like him, we will also keep working with UEFA, to explore innovative digital solutions that improve fans’ experiences while enjoying football.”
UEFA and AntChain, one of the technology brands of Ant Group, on June 10 announced a five-year global partnership to jointly explore using blockchain technology to accelerate the digital transformation of the football industry and improve the experiences of fans across the globe. Under the agreement, AntChain became the official global blockchain partner of UEFA EURO 2020.
To honor the performances of the top scoring players, an AntChain-developed digital record of highlights from the UEFA EURO 2020 top scorers will be preserved at UEFA’s headquarters, making it the first digital collectible in the history of the EURO Top Scorer.
“The top scoring moments digital collectible will serve as a lasting memento, encouraging football fans around the world to spread the team spirit and happiness that are part and parcel of this beloved sport,” said Mr. Jing.
The UEFA EURO 2020 Top Scorer trophies are designed by Alipay, the world’s leading digital payment and lifestyle platform operated by Ant Group, which has been UEFA’s global partner since November 2018.
On June 12, UEFA launched a new mini program with Alipay to improve engagement with mobile-savvy Chinese football fans. Dubbed the UEFA EURO 2020 Official Digital Hub, the mini program offers football fans across China an inside look at the tournament through regular news updates, interviews with key players, and much more. The UEFA mini program has rapidly become the most popular sports-focused mini program on Alipay, attracting over 12 million users as of July 11.
During the tournament, Alipay launched a campaign via the UEFA EURO 2020 Dream Tour mini program that enables authenticated users to earn points by engaging in various fan activities. Powered by AntChain's technologies, the top 1,600 users will receive gold, silver, and bronze digital trophies as a form of digital souvenir with certificates on a blockchain.
Alipay also launched "Top Scorers on Campus,” a new advocacy program dedicated to supporting the development of campus football in China. To inspire more teenagers to pursue their football dreams, the program will award trophies with the same design as the Alipay Top Scorer Gold Trophy of the UEFA EURO 2020 to the best young players in campus football tournaments across China. Similar to the UEFA EURO 2020 Top Scorer Trophy, these students’ scoring records and achievements will also be stored on a blockchain provided by AntChain.
About AntChain
AntChain is one of Ant Group’s technology brands. According to IPR Daily and patent database IncoPat, Ant Group held the highest number of published blockchain-related patent applications between 2017 and the six months ended June 30, 2020. Since the launch of Ant Group’s blockchain business in 2016, the company has pioneered the use of AntChain in over 50 blockchain commercial applications and use cases, including supply chain finance, cross-border remittance, charitable donations, and product provenance.
About Alipay
Alipay is the leading digital payment platform in China, serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, the global cross-border mobile payments and marketing solution which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom